Unilife Corporation (Unilife) is a developer and commercial supplier injectable drug delivery systems. The Company builds long-term collaborations with pharmaceutical and biotechnology companies seeking to utilize its differentiated devices to enable or enhance the clinical development, regulatory approval and lifecycle management of their injectable therapies. The Company device portfolio is suitable for use with brand name, generic or biosimilar drugs and vaccines supplied in either a liquid stable or lyophilized format for delivery via administration routes including subcutaneous injection. Prefilled Syringes with Integrated Needle Retraction, Auto-Injectors, Drug Reconstitution Delivery Systems, Bolus Injectors and Specialized Delivery Systems. It focuses on the design, development, manufacture and supply of a range of retractable syringes. Its principal product is the Unifill ready-to-fill syringe.
|Headquarters||250 Cross Farm Lane|
YORK, PA, United States 17406
|Chief Executive Officer, Executive Director||Alan Shortall|
|Chief Financial Officer, Executive Vice President||R. Richard Wieland|
|Chief Operating Officer, Executive Vice President||Ramin Mojdehbakhsh|
|Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary||J. Christopher Naftzger|
|Vice President - Quality and Regulatory Affairs||Mark Iampietro|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||89.8M||Book Value||$0.58|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||103.7|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-1,633.19%|
*GAAP = prior to non-GAAP analyst adjusted earnings.